With Klygefa approvals, AZ expands myasthenia gravis domain beyond Soliris, Ultomiris

Green light, double green light, approval, approvals, FDA, FDA nod
In both the U.S. and the European Union, gefurulimab is now approved under the commercial moniker Klygefa as a new treatment for gMG in adults who are anti-acetylcholine receptor antibody positive. (Dario Truco/iStock/Getty Images Plus)

Continuing to harvest a bounty of autumn approvals, AstraZeneca has picked up nods for its C5 inhibitor gefurulimab to treat generalized myasthenia gravis (gMG) on both sides of the Atlantic. 

The dual decisions from U.S. and European regulators are expected to gird AZ and its subsidiary Alexion’s business as earlier gMG treatment Soliris weathers biosimilar competition. They come hot on the heels of another FDA green light for a cocktail of AZ’s Imfinzi and Pfizer and Astellas’ Padcev in a tough-to-treat form of bladder cancer.

In both the U.S. and the European Union, gefurulimab is now approved under the commercial moniker Klygefa as a new treatment for gMG in adults who are anti-acetylcholine receptor (AChR) antibody positive.

Unlike the suite of FcRn blockers that have come to dominate targeted gMG treatment interventions, Klygefa brings a more unique mechanism to bear against the rare autoimmune disorder by blocking the complement component C5, placing it on comparable footing to UCB’s Zilbrysq (zilucoplan). 

The drug can be self-administered from home once weekly via an autoinjector, AZ announced in separate U.S. and EU releases on Nov. 16. In the case of the European go-ahead, formal clearance from the European Commission has arrived after the European Medicines Agency’s human medicines committee recommended Klygefa for approval in September. 

Generalized myasthenia gravis is a rare autoimmune disorder that impairs neuromuscular communication, in turn hampering muscle functioning and leading to severe muscle weakness. The condition is estimated to affect some 98,500 people in the U.S., among whom around 81,000 are AchR-positive, aligning with Klygefa’s label. 

Overseas, AZ has identified a diagnosed gMG population of roughly 82,500 people across 5 European countries (Germany, France, the U.K., Italy and Spain), with around 66,000 of those people AChR-positive. At past investor days, the company has forecasted potential sales for Klygefa in the $1-billion-to-$3-billion ballpark. 

Still, AZ will have its work cut out as it introduces Klygefa into an increasingly crowded therapeutic landscape. 

Targeted treatment of gMG has witnessed a surge in approvals this decade, with the trend kicking off in earnest with the original green light for argenx’s FcRn blocker Vyvgart in late 2021. Since then, multiple other therapeutic options for gMG have come to the fore, including Amgen’s Uplizna, Johnson & Johnson’s Imaavy and a second UCB gMG treatment in Rystiggo.

Plus, argenx has increasingly shifted focus to its own subcutaneous formulation of its drug efgartigimod in Vyvgart Hytrulo, also approved for at-home administration and which expanded its U.S. label earlier this year to capture all gMG patient serotypes in adults. 

AZ and Alexion, for their parts, leveraged data from their late-stage Prevail study of Klygefa to secure the new U.S. and EU approvals. In the 260-person study, Klygefa was tied to a primary endpoint beat by helping patients improve from baseline on the Myasthenia Gravis Activities of Daily Living (MG-ADL) clinical tool versus placebo at week 26. AZ also noted that clinical improvement on Klygefa was observed as early as one week into Prevail.

“The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector,” Marc Dunoyer, chief of AZ’s rare disease unit Alexion, said in a statement. 

Outside the U.S. and Europe, Klygefa snagged its world-first green light in Japan in late August. 

The nods mark AZ and Alexion’s next move in gMG, where the companies already operate with complement inhibitor Soliris—approved in a range of rare autoimmune and blood disorders and now facing biosimilar competition in the U.S.—and long-acting successor medication Ultomiris, which is given intravenously and also has a wider remit than the gMG-focused Klygefa to treat conditions like paroxysmal nocturnal hemoglobinuria, neuromyelitis optica spectrum disorder and immunoglobulin A nephropathy (IgAN).

Ultomiris, which continued its label expansion sprint as recently as October with the FDA nod in IgAN, continues to constitute a sales linchpin for AstraZeneca, delivering 19% growth to $4.7 billion in global sales last year. 

As Soliris sales decline in the face of copy-cat competition, AZ has been working to convert patients over to Ultomiris.